Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy

Kidney International

Volumn 76, Issue 12, 2009, Pages 1248-1257

  Tan, Xiaoyue ^a   He, Weichun ^b   Liu, Youhua ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

ACEI; Combined therapy; Inflammation; Renal fibrosis; Vitamin D

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; PARICALCITOL; RANTES; RENIN; TRANDOLAPRIL; TRANSCRIPTION FACTOR SNAIL; TUMOR NECROSIS FACTOR ALPHA; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; ENZYME REPRESSION; INFLAMMATION; KIDNEY DISEASE; KIDNEY FIBROSIS; MACROPHAGE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; OBSTRUCTIVE NEPHROPATHY; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; T LYMPHOCYTE; URETER OBSTRUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BASE SEQUENCE; BASEMENT MEMBRANE; CHEMOKINE CCL5; COLLAGEN; DNA PRIMERS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ERGOCALCIFEROLS; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; GENE EXPRESSION; INDOLES; MACROPHAGES; MALE; MICE; RENAL INSUFFICIENCY, CHRONIC; RENIN; RNA, MESSENGER; T-LYMPHOCYTES; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA; URETERAL OBSTRUCTION; VIMENTIN;

EID: 71149113180     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.346     Document Type: Article

References (48)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047. (Pubitemid 350074801)
2. White SL, Cass A, Atkins RC et al. Chronic kidney disease in the general population. Adv Chronic Kidney Dis 2005; 12: 5-13.
3. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl 2005; 98: S7-S10. (Pubitemid 43307841)
4. Eknoyan G, Lameire N, Barsoum R et al. The burden of kidney disease: improving global outcomes. Kidney Int 2004; 66: 1310-1314.
5. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869. (Pubitemid 34940825)
6. Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140.
7. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006; 1: 221-228.
8. Nguyen G, Contrepas A. Physiology and pharmacology of the (pro)renin receptor. Curr Opin Pharmacol 2008; 8: 127-132.
9. Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427.
10. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-217. (Pubitemid 43323069)
11. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12: 353-365.
12. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
13. LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45: 1026-1033.
14. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125.
15. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828.
16. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456. (Pubitemid 36910023)
17. Wolf M, Thadhani R. Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J Steroid Biochem Mol Biol 2007; 103: 487-490.
18. Shoben AB, Rudser KD, de Boer IH et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619.
19. Coen G. Vitamin D: an old prohormone with an emergent role in chronic kidney disease. J Nephrol 2008; 21: 313-323.
20. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382-3393.
21. Kuhlmann A, Haas CS, Gross ML et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-F533.
22. Freundlich M, Quiroz Y, Zhang Z et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74: 1394-1402.
23. Mizobuchi M, Morrissey J, Finch JL et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-1806.
24. Zhang Z, Zhang Y, Ning G et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 105: 15896-15901.
25. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kB signaling. J Am Soc Nephrol 2008; 19: 1741-1752.
26. Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238.
27. Andress D. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 2007; 67: 1999-2012.
28. Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-1490.
29. Fryer RM, Rakestraw PA, Nakane M et al. Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 2007; 106: 76-81.
30. Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715.
31. Yoshino J, Monkawa T, Tsuji M et al. Snail1 is involved in the renal epithelial-mesenchymal transition. Biochem Biophys Res Commun 2007; 362: 63-68.
32. Boutet A, De Frutos CA, Maxwell PH et al. Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. EMBO J 2006; 25: 5603-5613.
33. Chevalier RL, Forbes MS, Thornhill BA. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009; 75: 1145-1152.
34. Brancaccio D, Bommer J, Coyne D. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. Drugs 2007; 67: 1981-1998.
35. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43.
36. Repo JM, Rantala IS, Honkanen TT et al. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int 2007; 72: 977-984.
37. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
38. Iwano M, Plieth D, Danoff TM et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110: 341-350.
39. Carvajal G, Rodriguez-Vita J, Rodrigues-Diez R et al. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int 2008; 74: 585-595.
40. Rodrigues-Diez R, Carvajal-Gonzalez G, Sanchez-Lopez E et al. Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharm Res 2008; 25: 2447-2461.
41. Li YC. Inhibition of renin: an updated review of the development of renin inhibitors. Curr Opin Investig Drugs 2007; 8: 750-757.
42. Cui R, Tieu B, Recinos A et al. RhoA mediates angiotensin II-induced phospho-Ser536 nuclear factor kappaB/RelA subunit exchange on the interleukin-6 promoter in VSMCs. Circ Res 2006; 99: 723-730.
43. Zhang L, Cheng J, Ma Y et al. Dual pathways for nuclear factor kappaB activation by angiotensin II in vascular smooth muscle: phosphorylation of p65 by IkappaB kinase and ribosomal kinase. Circ Res 2005; 97: 975-982.
44. Yang J, Liu Y. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. J Am Soc Nephrol 2002; 13: 96-107.
45. He W, Dai C, Li Y et al. Wnt/b-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009; 20: 765-776.
46. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465-1475.
47. Giannopoulou M, Dai C, Tan X et al. Hepatocyte growth factor exerts its anti-inflammatory action by disrupting NF-kB signaling. Am J Pathol 2008; 173: 30-41.
48. Englert JM, Hanford LE, Kaminski N et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008; 172: 583-591.